Ovid Therapeutics Inc.
OVIDNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for OVID. That does not mean none is planned.
Get an email about OVID's next catalysts
Track Ovid Therapeutics (OVID) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
OVID Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.08 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OV101 (gaboxadol) | Phase 2 | Fragile X Syndrome (FXS) | - | - |
Frequently asked questions
What is in Ovid Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Ovid Therapeutics Inc.'s (OVID) pipeline across Phase 2. Its lead program is OV101 (gaboxadol) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ovid Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ovid Therapeutics Inc. (OVID) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OVID biotech catalysts?→
Add OVID to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ovid Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.